Literature DB >> 19843676

Reproducibility of fifteen urinary estrogens and estrogen metabolites over a 2- to 3-year period in premenopausal women.

A Heather Eliassen1, Regina G Ziegler, Bernard Rosner, Timothy D Veenstra, John M Roman, Xia Xu, Susan E Hankinson.   

Abstract

Endogenous estrogens play an integral role in the etiology of breast, endometrial, and, possibly, ovarian cancers. Estrogen metabolism yields products that are potentially both estrogenic and genotoxic, yet individual metabolic patterns are just beginning to be explored in epidemiologic studies. Within the Nurses' Health Study II, we examined reproducibility of 15 urinary estrogens and estrogen metabolites (EM) among 110 premenopausal women with three luteal-phase urine samples collected over 3 years. EM were measured by a recently developed high-performance liquid chromatography-tandem mass spectrometry (LC-MS(2)) method with high sensitivity, specificity, and precision. We assessed Spearman correlations and intraclass correlation coefficients (ICC) across the three samples. Correlations between urinary estrone or estradiol and EM were only modest (r = 0.1-0.5). The 2- and 4-hydroxylation pathways were highly correlated (r = 0.9) but weakly inversely correlated with the 16-hydroxylation pathway (r = -0.2). Within-woman reproducibility over time was fairly high for the three pathways, with ICCs ranging from 0.52 (16-hydroxylation pathway) to 0.72 (2-hydroxylation pathway). ICCs were similarly high for 2-catechols and the individual catechols (ICCs = 0.58-0.72). Individual and grouped methylated 2-catechols had fairly high ICCs (0.51-0.62), but methylated 4-catechols had low ICCs (0.14-0.27). These data indicate that, in general, urinary EM levels vary substantially among individuals compared with intraindividual variability. Within-person reproducibility over time for most EM measures is comparable to or better than that for well-vetted biomarkers such as plasma cholesterol and, in postmenopausal women, estradiol.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19843676      PMCID: PMC2783292          DOI: 10.1158/1055-9965.EPI-09-0591

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  59 in total

1.  Age-specific correlation analysis of longitudinal blood pressure data.

Authors:  B Rosner; C H Hennekens; E H Kass; W E Miall
Journal:  Am J Epidemiol       Date:  1977-10       Impact factor: 4.897

2.  Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection.

Authors:  Jay H Fowke; Dai Qi; H Leon Bradlow; Xiao Ou Shu; Yu Tang Gao; Jin Rong Cheng; Fan Jin; Wei Zheng
Journal:  Steroids       Date:  2003-01       Impact factor: 2.668

3.  Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women.

Authors:  P Muti; H L Bradlow; A Micheli; V Krogh; J L Freudenheim; H J Schünemann; M Stanulla; J Yang; D W Sepkovic; M Trevisan; F Berrino
Journal:  Epidemiology       Date:  2000-11       Impact factor: 4.822

4.  Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies.

Authors:  T Key; P Appleby; I Barnes; G Reeves
Journal:  J Natl Cancer Inst       Date:  2002-04-17       Impact factor: 13.506

Review 5.  Tissue-specific synthesis and oxidative metabolism of estrogens.

Authors:  C R Jefcoate; J G Liehr; R J Santen; T R Sutter; J D Yager; W Yue; S J Santner; R Tekmal; L Demers; R Pauley; F Naftolin; G Mor; L Berstein
Journal:  J Natl Cancer Inst Monogr       Date:  2000

6.  Endogenous sex hormones and subsequent breast cancer in premenopausal women.

Authors:  Andrea Micheli; Paola Muti; Giorgio Secreto; Vittorio Krogh; Elisabetta Meneghini; Elisabetta Venturelli; Sabina Sieri; Valeria Pala; Franco Berrino
Journal:  Int J Cancer       Date:  2004-11-01       Impact factor: 7.396

7.  Estrogen metabolites and the risk of breast cancer in older women.

Authors:  Jane A Cauley; Joseph M Zmuda; Michelle E Danielson; Britt-Marie Ljung; Douglas C Bauer; Steven R Cummings; Lewis H Kuller
Journal:  Epidemiology       Date:  2003-11       Impact factor: 4.822

8.  The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells.

Authors:  C Lippert; H Seeger; A O Mueck
Journal:  Life Sci       Date:  2003-01-10       Impact factor: 5.037

9.  Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells.

Authors:  Zhi-Jian Liu; Bao Ting Zhu
Journal:  J Steroid Biochem Mol Biol       Date:  2004-03       Impact factor: 4.292

Review 10.  Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis.

Authors:  W Yue; R J Santen; J-P Wang; Y Li; M F Verderame; W P Bocchinfuso; K S Korach; P Devanesan; R Todorovic; E G Rogan; E L Cavalieri
Journal:  J Steroid Biochem Mol Biol       Date:  2003-09       Impact factor: 4.292

View more
  32 in total

1.  Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women.

Authors:  A Heather Eliassen; Donna Spiegelman; Xia Xu; Larry K Keefer; Timothy D Veenstra; Robert L Barbieri; Walter C Willett; Susan E Hankinson; Regina G Ziegler
Journal:  Cancer Res       Date:  2011-12-05       Impact factor: 12.701

Review 2.  Epidemiologic studies of estrogen metabolism and breast cancer.

Authors:  Regina G Ziegler; Barbara J Fuhrman; Steven C Moore; Charles E Matthews
Journal:  Steroids       Date:  2015-02-26       Impact factor: 2.668

3.  Estrogen Metabolism in Premenopausal Women Is Related to Early Life Body Fatness.

Authors:  A Heather Eliassen; Regina G Ziegler; Lauren C Houghton; Julia S Sisti; Susan E Hankinson; Jing Xie; Xia Xu; Robert N Hoover
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-03-06       Impact factor: 4.254

4.  Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses' Health Studies.

Authors:  Joanne Kotsopoulos; Shelley S Tworoger; Hannia Campos; Fung-Lung Chung; Charles V Clevenger; Adrian A Franke; Christos S Mantzoros; Vincent Ricchiuti; Walter C Willett; Susan E Hankinson; A Heather Eliassen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-23       Impact factor: 4.254

5.  The relation of urinary estrogen metabolites with mammographic densities in premenopausal women.

Authors:  Gertraud Maskarinec; Sreang Heak; Yukiko Morimoto; Laurie Custer; Adrian A Franke
Journal:  Cancer Epidemiol       Date:  2012-04-25       Impact factor: 2.984

6.  Analgesic use and patterns of estrogen metabolism in premenopausal women.

Authors:  Renée T Fortner; Hannah Oh; Sarah E Daugherty; Xia Xu; Susan E Hankinson; Regina G Ziegler; A Heather Eliassen
Journal:  Horm Cancer       Date:  2014-01-10       Impact factor: 3.869

7.  The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk.

Authors:  Marian Y Williams-Brown; Sana M Salih; Xia Xu; Timothy D Veenstra; Muhammad Saeed; Shaleen K Theiler; Concepcion R Diaz-Arrastia; Salama A Salama
Journal:  J Steroid Biochem Mol Biol       Date:  2011-05-10       Impact factor: 4.292

8.  Caffeine, coffee, and tea intake and urinary estrogens and estrogen metabolites in premenopausal women.

Authors:  Julia S Sisti; Susan E Hankinson; Neil E Caporaso; Fangyi Gu; Rulla M Tamimi; Bernard Rosner; Xia Xu; Regina Ziegler; A Heather Eliassen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-06-10       Impact factor: 4.254

9.  Association between physical activity and urinary estrogens and estrogen metabolites in premenopausal women.

Authors:  Charles E Matthews; Renee T Fortner; Xia Xu; Susan E Hankinson; A Heather Eliassen; Regina G Ziegler
Journal:  J Clin Endocrinol Metab       Date:  2012-08-01       Impact factor: 5.958

10.  Importance of estrogen metabolites.

Authors:  Sarah H Lindsey
Journal:  Hypertension       Date:  2014-04-28       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.